Selection bias

occurs when individuals or groups in a study differ systematically from the population of interest leading to a systematic error in an association or outcome.

Background

Participants in research may differ systematically from the population of interest.  For example, participants included in an influenza vaccine trial may be healthy young adults, whereas those who are most likely to receive the intervention in practice may be elderly and have many comorbidities, and are therefore not representative. Similarly, in observational studies, conclusions from the research population may not apply to real-world people, as the observed effect may be exaggerated or it is not possible to assume an effect in those not included in the study.

Selection bias can arise in studies because groups of participants may differ in ways other than the interventions or exposures under investigation. When this is the case, the results of the study are biased by confounding.

Example

A study of the prevalence of Parkinson’s disease (PD) completed a door to door survey of an entire US county. They used a two-stage screening technique, first administering a comprehensive questionnaire and then referring those subjects with signs or symptoms suggestive of PD for a neurological evaluation. Over 97% of the households in the county participated. Some 15% of those screening positive in the first screen refused follow-up. Extensive efforts provided ‘valuable information on almost all the refusals which was reviewed by a neurologist to establish a diagnosis’. The authors presented convincing evidence that they had succeeded in obtaining a complete enumeration of PD cases in the county.

Of the approximately 24,000 residents on prevalence day, 1 January 1978, PD was diagnosed in 31 participants. Thirteen of those 31 had never been seen for medical care. In this survey, if another approach to the ascertainment of cases had used only the medical care system, all of those who had not received care (over 40%) would not have been identified. Furthermore, there would have been no definitive way of characterizing the bias introduced if only those identified via health records were used.

Another example is the effect of HRT on coronary heart disease (CHD) in women. Several studies showed that HRT reduced coronary heart disease (CHD), but subsequent RCTs showed that HRT might increase the risk of CHD disease. The Women in the observational studies on HRT were more health conscious, more physically active, and had higher socioeconomic status than those not on HRT. This self-selection of women (selection bias) led to confounding and a “healthy-user bias”.

In a double-blind placebo-controlled study of the use of phenobarbital for prevention of recurrent febrile seizures, adherence was not as good as hoped. The Kaplan-Meier curves for remaining free from seizures were not statistically significantly different from each other, contrary to expectation. The authors used several definitions of adherence and reanalysed the results ‘as treated’. The results based on one definition of adherence showed that adherent subjects in both the phenobarbital and the placebo groups had a higher risk of recurrence than those who were non-adherent. The results were thus conflicting and demonstrated selection bias due to attrition.

Prospective cohort studies of dietary and lifestyle factors exhibit a “healthy participant effect”, reporting lower mortality rates among participants than among the general population. This suggests that people who are interested in healthy lifestyles, and therefore have more healthy behaviours, such as low smoking rates, are more likely to sign up to take part in a prospective study than those with less healthy lifestyles. This can also be considered a sampling bias

A study of cigarette smoking and dementia found potential selection bias in the elderly. Selection bias due to censoring by death was one explanation for the lower relative rate of dementia in smokers with increasing age.

Impact

Selection bias can have varying effects, and the magnitude of its impact and the direction of the effect is often hard to determine. (Odgaard-Jensen J et al.)

As examples, a meta-epidemiological study of the Impact of Selection Bias on Treatment Effect Size Estimates in Randomized Trials of Oral Health Interventions found significantly larger treatment effect estimates in trials that had inadequate/unknown sequence generation (difference in ES = 0.13; 95% CI: 0.01 to 0.25). A further study to determine survival in preterm infant cohort studies found that the presence of selection bias overestimated survival by as much as 100%.

Preventive steps

To assess the probable degree of selection bias, authors should include the following information at different stages of the trial or study:

– Numbers of participants screened as well as randomised/included.

– How intervention/exposure groups compared at baseline.

– To what extent potential participants were re-screened.

– Exactly what procedures were put in place to prevent prediction of future allocations and knowledge of previous allocations.

– What the restrictions were on randomisation, e.g. block sizes.

– Any evidence of unblinding.

– How missing data from participants lost to follow-up were handled.

Randomisation of participants in intervention studies aims to provide the fairest method of comparing the effect of an intervention with a control, and preventing selection biases is part of this aim. However, it may not be perfectly achieved. Berger and colleagues have made clear arguments for the crucial role of adequate allocation concealment and randomisation procedures to prevent selection biases.

Because anything that happens after randomisation can affect the chance that a study participant has the outcome of interest, it is essential that all patients (even those who fail to take their medicine or accidentally or intentionally receive the wrong treatment) are analysed in the groups to which they were allocated. The intention-to-treat analysis includes data from all the participants randomly assigned to the treatment comparison groups, whether or not they received the treatment to which they were assigned, even if they never started the treatment, or switched to a different one during the study. This prevents bias caused by disruption of the baseline equivalence established by random allocation.

In Observational studies selection bias is difficult to address with analytical methods, but methods for dealing with missing data are available, including last observation (or baseline value) carried forward, mixed models, imputation, and sensitivity analysis using ‘worst case’ scenarios (assuming that those with no information all got worse) and ‘best case’ scenarios (assuming that all got better). Analysing data only from participants remaining in the study is called complete case analysis.

Certain external measures can sometimes be used to calibrate the data from a study, an example being standardised mortality rates. Moreover, inverse probability weighting can be used under certain assumptions.

To improve generalisability of study findings the selection of the population should be broad and reported in the recruitment/inclusion criteria.

Sources

Berger VW et al. Randomization technique, allocation concealment, masking, and susceptibility of trials to selection bias. J Mod Appl Stat Methods 2003; 2(1): 80-6.

CASS Principal Investigators and Their Associates. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Comparability of entry characteristics and survival in randomized patients and nonrandomized patients meeting randomization criteria. J Am Coll Cardiol 1984; 3(1): 114-28.

Farwell JR et al. Phenobarbital for febrile seizures–effects on intelligence and on seizure recurrence. N Engl J Med 1990; 322(6): 364-9.

Key TJ et al. Mortality in British vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford). Am J Clin Nutr 2009; 89(5): 1613S-1619S.

Odgaard-Jensen J et al.Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2011 Apr 13; (4): MR000012. https://www.ncbi.nlm.nih.gov/pubmed/21491415

Schoenberg BS et al. Prevalence  of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 1985; 35(6): 841-5.

Sundt TM Jr. Was the international randomized trial of extracranial-intracranial arterial bypass representative of the population at risk? N Engl J Med 1987; 316(13): 814-6.

Hernán MA et al. Cigarette smoking and dementia: potential selection bias in the elderly. Epidemiology. 2008 May;19(3):448-50. doi: 10.1097/EDE.0b013e31816bbe14

Saltaji H et al. Impact of Selection Bias on Treatment Effect Size Estimates in Randomized Trials of Oral Health Interventions: A Meta-epidemiological Study. J Dent Res. 2018 Jan;97(1):5-13. doi: 10.1177/0022034517725049. Epub 2017 Aug 16.

Evans DJ et al. Evidence of selection bias in preterm survival studies: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2001 Mar;84(2):F79-84. Review.

Odgaard-Jensen J et al.  Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev. 2011 Apr 13;(4):MR000012. doi: 10.1002/14651858.MR000012.pub3.

 


PubMed feed

These sources are retrieved dynamically from PubMed:

View more →

Leave a Reply

Your email address will not be published. Required fields are marked *